Evidence map›Paper›PMID 35405168›Full record

Trial reportThe Journal of infection2022

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

Xinxue Liu, Alasdair P S Munro, Shuo Feng, Leila Janani, Parvinder K Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee and 49 more

Erratum issuedOpen access · hybridAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 64 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

59 authors at 20 institutions in 1 country.

Xinxue LiuOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. Electronic address: xinxue.liu@paediatrics.ox.ac.uk.
Alasdair P S MunroNIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
Shuo FengOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Leila JananiImperial Clinical Trials Unit, Imperial College London, London, UK.
Parvinder K AleyOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Gavin BabbageNIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
David BaxterStockport NHS Foundation Trust, Stockport, UK.
Marcin BulaNIHR Liverpool and Broadgreen Clinical Research Facility, Liverpool, UK.
Katrina CathieNIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
Krishna ChatterjeeNIHR Cambridge Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Wanwisa DejnirattisaiWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Kate DoddNIHR Liverpool and Broadgreen Clinical Research Facility, Liverpool, UK.
Yvanne EneverPHARMExcel. Welwyn Garden City, Hertfordshire, UK.
Ehsaan QureshiNIHR/Wellcome Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Anna L GoodmanDepartment of Infection, Guy's and St Thomas' NHS Foundation Trust, London, UK; MRC Clinical Trials Unit, University College London, London, UK.
Christopher A GreenNIHR/Wellcome Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Linda HarndahlPortsmouth Hospitals University NHS Trust, Portsmouth, UK.
John HaughneyQueen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, UK.
Alexander HicksPortsmouth Hospitals University NHS Trust, Portsmouth, UK.
Agatha A van der KlaauwWellcome-MRC Institute of Metabolic Science, Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK.
Jonathan KwokCancer Research UK Oxford Centre, University of Oxford, Oxford, UK.
Vincenzo LibriNIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.
Martin J LlewelynUniversity Hospitals Sussex NHS Foundation Trust, Brighton, UK.
Alastair C McGregorDepartment of Infectious Diseases and Tropical Medicine, London Northwest University Healthcare, London, UK.
Angela M MinassianOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Patrick MooreThe Adam Practice, Poole, UK.
Mehmood MughalStockport NHS Foundation Trust, Stockport, UK.
Yama F MujadidiNIHR Oxford Biomedical Research Centre, Oxford, UK.
Kyra HollidayNIHR Leeds Clinical Research Facility, Leeds Teaching Hospitals Trust and University of Leeds, Leeds, UK.
Orod OsanlouPublic Health Wales, Betsi Cadwaladr University Health Board, Bangor University, Bangor, UK.
Rostam OsanlouUniversity of Liverpool, Liverpool, UK.
Daniel R OwensNIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
Mihaela PacurarNIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
Adrian PalfreemanUniversity Hospitals of Leicester NHS Trust, University of Leicester, Leicester, UK.
Daniel PanUniversity Hospitals of Leicester NHS Trust, University of Leicester, Leicester, UK.
Tommy RamplingNIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.
Karen ReganBradford Institute for Health Research and Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.
Stephen SaichNIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Teona SerafimovaDepartment of Infection, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Dinesh SaralayaBradford Institute for Health Research and Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.
Gavin R ScreatonWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Sunil SharmaUniversity Hospitals Sussex NHS Foundation Trust, Brighton, UK.
Ray SheridanRoyal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK.
Ann SturdyDepartment of Infectious Diseases and Tropical Medicine, London Northwest University Healthcare, London, UK.
Piyada SupasaWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Emma C ThomsonQueen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, UK; MRC University of Glasgow Centre for Virus Research, Glasgow, UK.
Shirley ToddRoyal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK.
Chris TwelvesNIHR Leeds Clinical Research Facility, Leeds Teaching Hospitals Trust and University of Leeds, Leeds, UK.
Robert C ReadNIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
Sue CharltonUK Health Security Agency, Porton Down, UK.
Bassam HallisUK Health Security Agency, Porton Down, UK.
Mary RamsayUK Health Security Agency, Colindale, London, UK.
Nick AndrewsUK Health Security Agency, Colindale, London, UK.
Teresa LambeOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Jonathan S Nguyen-Van-TamDivision of Epidemiology and Public Health, University of Nottingham School of Medicine.
Victoria CorneliusImperial Clinical Trials Unit, Imperial College London, London, UK.
Matthew D SnapeOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Saul N FaustNIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK. Electronic address: s.faust@soton.ac.uk.
COV-BOOST study group
University Hospital Southampton NHS Foundation Trust · GBUniversity of Oxford · GBUK Health Security Agency · GBCentre for Human Genetics · GBBradford Teaching Hospitals NHS Foundation Trust · GBBroadgreen Hospital · GBGuy's and St Thomas' NHS Foundation Trust · GBImperial College London · GBNHS Greater Glasgow and Clyde · GBPortsmouth Hospitals NHS Trust · GBRoyal Devon & Exeter NHS Foundation Trust · GBStockport NHS Foundation Trust · GBUCL Biomedical Research Centre · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity Hospitals Sussex NHS Foundation Trust · GBUniversity of Leeds · GBUniversity of Leicester · GBBetsi Cadwaladr University Health Board · GBCambridge University Hospitals NHS Foundation Trust · GBHertfordshire Community NHS Trust · GB

Funding

Medical Research Council MC_PC_19026Medical Research Council MC_UU_00004/04Medical Research Council MR/N013204/1Medical Research Council MR/N026993/1
6 · The paper itself

Abstract

objectivesTo evaluate the persistence of immunogenicity three months after third dose boosters.

methodsCOV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster dose. The analysis was conducted using all randomised participants who were SARS-CoV-2 naïve during the study.

resultsAmongst the 2883 participants randomised, there were 2422 SARS-CoV-2 naïve participants until D84 visit included in the analysis with median age of 70 (IQR: 30-94) years. In the participants who had two initial doses of ChAdOx1 nCov-19 (Oxford-AstraZeneca; hereafter referred to as ChAd), schedules using mRNA vaccines as third dose have the highest anti-spike IgG at D84 (e.g. geometric mean concentration of 8674 ELU/ml (95% CI: 7461-10,085) following ChAd/ChAd/BNT162b2 (Pfizer-BioNtech, hearafter referred to as BNT)). However, in people who had two initial doses of BNT there was no significant difference at D84 in people given ChAd versus BNT (geometric mean ratio (GMR) of 0.95 (95%CI: 0.78, 1.15). Also, people given Ad26.COV2.S (Janssen; hereafter referred to as Ad26) as a third dose had significantly higher anti-spike IgG at D84 than BNT (GMR of 1.20, 95%CI: 1.01,1.43). Responses at D84 between people who received BNT (15 μg) or BNT (30 μg) after ChAd/ChAd or BNT/BNT were similar, with anti-spike IgG GMRs of half-BNT (15 μg) versus BNT (30 μg) ranging between 0.74-0.86. The decay rate of cellular responses were similar between all the vaccine schedules and doses.

conclusions84 days after a third dose of COVID-19 vaccine the decay rates of humoral response were different between vaccines. Adenoviral vector vaccine anti-spike IgG concentrations at D84 following BNT/BNT initial doses were similar to or even higher than for a three dose (BNT/BNT/BNT) schedule. Half dose BNT immune responses were similar to full dose responses. While high antibody tires are desirable in situations of high transmission of new variants of concern, the maintenance of immune responses that confer long-lasting protection against severe disease or death is also of critical importance. Policymakers may also consider adenoviral vector, fractional dose of mRNA, or other non-mRNA vaccines as third doses.

Indexed as

COVID-19Viral VaccinesAd26COVS1AdultAgedAged, 80 and overAntibodies, ViralBNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesHumansImmunogenicity, VaccineImmunoglobulin GMiddle AgedmRNA VaccinesSARS-CoV-2Ad26COVS1Antibodies, ViralBNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesImmunoglobulin GmRNA VaccinesViral VaccinesCOVID-19 vaccineFractional doseHeterologous boostHomologous boostImmunogenicityPersistenceThird dose

Identifiers

PMID35405168
PMCPMC8993491
OpenAlexW4223599029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.